He is a founding author of the investing group The Dividend Kings which focuses on helping investors safeguard and grow their money in all market conditions through the highest-quality dividend investments. Dividend Sensei and the team of analysts (Brad Thomas, Justin Law, Nicholas Ward, Chuck Carnevale, and Sebastian Wolf) help members invest more intelligently in dividend stocks. Features include: 13 model portfolios, buy ideas, company research reports, and a thriving chat community for readers looking t ...

New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC)PHILADELPHIA, Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for ...

Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumorsPHILADELPHIA, Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for t ...

If you have found my strategies interesting, useful, or profitable, consider supporting my continued research by joining the Cyclical Investor's Club . It's only $400/year, and it's where I share my latest research and exclusive small-and-midcap ideas. Two-week trials are free. All stock investing is about risk vs. reward over time. If an investor isn't estimating the likely reward over a given time frame, like 5 or 10 years, and then comparing that to the inflation-adjusted risk over Cory leads the investi ...

Have you evaluated the performance of Genuine Parts' (GPC) international operations for the quarter ending September 2024? Given the extensive global presence of this auto and industrial parts distributor, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth jour ...

Shares fell after the company lowered 2024 earnings expectations.Genuine Parts (GPC -2.59%) shares fell hard this week after the global automotive and industrial parts giant reported some discouraging news about its short-term operating trends. The stock fell 20% through early Thursday trading, according to S&P Global Market Intelligence, compared to a modest decline for the S&P 500 index.That performance gap was due to Genuine Parts' Q3 earnings update, which showed surprisingly weak sales and profit trend ...

SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and subsequent institutional review board clearance to initiate patient enrollment in up to 7 academic centers for its c ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of GPC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice ...

Genuine Parts (NYSE: GPC ) just released its Q3 results, and given a lower outlook and a minus 19% in stock price performance in a single trading session, we are back to comment on our long-term position. This negative outcome isBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, informed as they might be, an ...

For the quarter ended September 2024, Genuine Parts (GPC) reported revenue of $5.97 billion, up 2.5% over the same period last year. EPS came in at $1.88, compared to $2.49 in the year-ago quarter.The reported revenue represents a surprise of -0.14% over the Zacks Consensus Estimate of $5.98 billion. With the consensus EPS estimate being $2.44, the EPS surprise was -22.95%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine t ...